Form 4: Xylem Inc. Executive Geri-Michelle McShane Reports Stock and Option Awards
SEC Form 4 Filing
Geri-Michelle McShane, VP, Controller & CAO of Xylem Inc., reports the acquisition of restricted stock units and non-qualified stock options.
Summary
- Geri-Michelle McShane, VP, Controller & CAO of Xylem Inc., filed a Form 4 on March 6, 2025, reporting transactions related to Xylem Inc. stock.
- On March 5, 2025, McShane acquired 530 shares of common stock at a price of $129.67 per share.
- These shares were awarded as restricted stock units under the Xylem 2011 Omnibus Incentive Plan, vesting in equal installments on March 5, 2026, March 5, 2027, and March 5, 2028.
- Additionally, McShane acquired 1,861 non-qualified stock options with an exercise price of $129.67, also vesting in one-third increments on March 5, 2026, March 5, 2027, and March 5, 2028.
- Following these transactions, McShane directly owns 4,950 shares of Xylem Inc. common stock and 1,861 non-qualified stock options.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. It doesn't contain information that would significantly impact investor sentiment positively or negatively.
Positives
- The grant of restricted stock units and stock options to a key executive like Geri-Michelle McShane aligns her interests with those of the shareholders.
- The vesting schedule of the awards (one-third increments over three years) encourages long-term commitment and performance.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's future performance.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The granting of stock options and restricted stock units is a common practice to incentivize executives and align their interests with shareholders.
Stakeholder Impact
- The granting of stock options and restricted stock units can positively impact shareholders by aligning executive interests with company performance.
- Employees may be indirectly impacted as executive performance can influence overall company success.
Key Dates
| Date | Description |
|---|---|
| February 24, 2016 | Date the Xylem 2011 Omnibus Incentive Plan was amended and restated. |
| March 5, 2025 | Date of the reported transactions: acquisition of stock and stock options. |
| March 5, 2026 | First vesting date for both the restricted stock units and non-qualified stock options. |
| March 5, 2027 | Second vesting date for both the restricted stock units and non-qualified stock options. |
| March 5, 2028 | Final vesting date for both the restricted stock units and non-qualified stock options. |
| March 5, 2035 | Expiration date for the non-qualified stock options. |
| March 6, 2025 | Date the Form 4 was signed. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.